With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.564483-19-8,Di-tert-butyl(2′,4′,6′-triisopropyl-[1,1′-biphenyl]-2-yl)phosphine,as a common compound, the synthetic route is as follows.
564483-19-8, Example 16 3-(3-tert-Butyl-5-phenoxy-phenyl)-1H-pyridin-2-one (I-45) step 1-A mixture of 3-(3-bromo-5-tert-butyl-phenyl)-2-methoxy-pyridine (123 mg, 0.384 mmol), phenol (46 mg, 0.489 mmol), Pd(OAc)2 (4.1 mg, 0.018 mmol), 2-di-tert-butylphosphino-2′,4′,6′-tri-isopropyl-1,1′-biphenyl (9.9 mg, 0.023 mmol) and K3PO4 (167 0.787 mmol)) in a Schlenk flask was purged with argon before toluene (5 mL) was added. The reaction under an argon atmosphere was heated overnight at 115 C. The reaction was cooled to RT, filtered through CELITE, and the filtrate was concentrated. The crude residue was purified by SiO2 chromatography eluding with an EtOAc/hexane gradient (0 to 2% EtOAc) to afford 40 mg (41%) of 3-(3-tert-butyl-5-phenoxy-phenyl)-2-methoxy-pyridine (124). step 2-A solution of 124 (52 mg, 0.157 mmol), 48% HBr (50 L, 0.436 mmol) and HOAc (3 mL) in sealed tube was heated at 70 C. overnight. The reaction mixture was cooled to RT, carefully poured into a cold saturated aqueous NaHCO3 and then extracted with EtOAc. The organic layer was washed with brine, dried (Na2SO4), filtered and concentrated. The crude residue was purified on a preparative SiO2 TLC plate developed with 66% EtOAc/hexanes to afford 48 mg (96%) of I-45 as a foam.
As the paragraph descriping shows that 564483-19-8 is playing an increasingly important role.
Reference£º
Patent; Roche Palo Alto LLC; US2010/21423; (2010); A1;,
Phosphine ligand
Chiral phosphine ligands in asymmetric synthesis. Molecular structure and absolute configuration of (1,5-cyclooctadiene)-(2S,3S)-2,3-bis(diphenylphosphino)butanerhodium(I) perchlorate tetrahydrofuran solvate